Physician profile
Thomas E Burkert
NPI 1801995618
$910.40
in general payments reported to CMS, 2019-2025
16 companies · $17.89 in 2025
The $17.89 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $486 · 2023: $28.16 · 2025: $17.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.76 | 2021-2022 | |
| Novo Nordisk INC | $203.16 | 2021-2023 | |
| Glaxosmithkline, LLC. | $74.16 | 2021-2022 | |
| Lilly USA, LLC | $72.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.69 | 2021-2025 | Entyvio, Trintellix |
| Amarin Pharma, INC. | $64.59 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.88 | 2021-2022 | |
| Almatica Pharma LLC | $23.00 | 2021 | |
| Phadia US INC. | $20.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.91 | 2022 | |
| Merck Sharp & Dohme LLC | $17.60 | 2021 | |
| Mylan Specialty L.P. | $15.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.10 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Burkert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.